Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 12, 2026
Monopar Therapeutics Inc. (MNPR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $5.3 million. As of Jun 30, 2026 it held $105.4 million in cash and investments and $205,663 in total debt.
Revenue
$0
Net income
$-5.31M
-116.6% vs year-ago quarter
Operating cash flow
$-3.25M
-201.4% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
6.71M
+8.8% vs year-ago quarter
Net cash
$105.16M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmette, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645469
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$6.6M | -$5.2M | -$6.2M | -$4.1M | -$3.2M |
| Net income | -$5.3M | -$3.9M | -$5.2M | -$3.4M | -$2.5M |
| Operating cash flow | -$3.2M | -$3.5M | -$3.4M | -$2.1M | -$1.1M |
| Total assets | $135.0M | $138.0M | $140.7M | $144.2M | $53.9M |
| Total liabilities | $4.1M | $2.6M | $2.9M | $2.6M | $1.7M |
| Stockholders' equity | $130.9M | $135.4M | $137.8M | $141.6M | $52.2M |
| Cash and investments | $105.4M | $104.9M | $122.7M | $255.2M | $78.8M |
| Total debt | $205,663 | $230,425 | $245,489 | $102,236 | $113,740 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
All 536 Monopar Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.